UY35425A - Compuestos y sus usos en la modulación de la hemoglobina - Google Patents
Compuestos y sus usos en la modulación de la hemoglobinaInfo
- Publication number
- UY35425A UY35425A UY35425A UY35425A UY35425A UY 35425 A UY35425 A UY 35425A UY 35425 A UY35425 A UY 35425A UY 35425 A UY35425 A UY 35425A UY 35425 A UY35425 A UY 35425A
- Authority
- UY
- Uruguay
- Prior art keywords
- hemoglobin
- compounds
- modulation
- methods
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/815,776 US9458139B2 (en) | 2013-03-15 | 2013-03-15 | Compounds and uses thereof for the modulation of hemoglobin |
| US201361905802P | 2013-11-18 | 2013-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35425A true UY35425A (es) | 2014-10-31 |
Family
ID=51580734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY35425A UY35425A (es) | 2013-03-15 | 2014-03-13 | Compuestos y sus usos en la modulación de la hemoglobina |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2970315B1 (enExample) |
| JP (2) | JP6401772B2 (enExample) |
| KR (1) | KR20150132147A (enExample) |
| CN (1) | CN105209469A (enExample) |
| AP (1) | AP2015008720A0 (enExample) |
| AU (1) | AU2014237361A1 (enExample) |
| BR (1) | BR112015021980A2 (enExample) |
| CA (1) | CA2902721C (enExample) |
| EA (1) | EA201591427A1 (enExample) |
| ES (1) | ES2909634T3 (enExample) |
| IL (1) | IL240845A0 (enExample) |
| MX (1) | MX388013B (enExample) |
| PE (1) | PE20151907A1 (enExample) |
| SG (1) | SG11201507351PA (enExample) |
| TW (1) | TW201518286A (enExample) |
| UY (1) | UY35425A (enExample) |
| WO (1) | WO2014150289A1 (enExample) |
| ZA (1) | ZA201506390B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| DK3738434T3 (da) | 2011-12-28 | 2023-12-04 | Global Blood Therapeutics Inc | Mellemprodukter til opnåelse af substituerede benzaldehydforbindelser og fremgangsmåder til anvendelse deraf ved øgning af vævsoxygenering |
| KR102280614B1 (ko) | 2013-03-15 | 2021-07-21 | 글로벌 블러드 테라퓨틱스, 인크. | 헤모글로빈 조정을 위한 화합물 및 이의 용도 |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| AU2014237330A1 (en) | 2013-03-15 | 2015-09-17 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| BR112015021982B1 (pt) | 2013-03-15 | 2022-12-13 | Global Blood Therapeutics, Inc | Compostos e seus usos para a modulação de hemoglobina |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| SI3102208T2 (sl) | 2014-02-07 | 2024-10-30 | Global Blood Therapeutics, Inc. | Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| SG10201913999PA (en) | 2015-10-16 | 2020-03-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
| US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11020382B2 (en) | 2015-12-04 | 2021-06-01 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| AR108435A1 (es) | 2016-05-12 | 2018-08-22 | Global Blood Therapeutics Inc | Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído |
| US10787430B2 (en) | 2016-06-17 | 2020-09-29 | Fronthera U.S. Pharmaceuticals Llc | Hemoglobin modifier compounds and uses thereof |
| TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
| JP7509772B2 (ja) * | 2018-11-19 | 2024-07-02 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンのモジュレーター |
| US11014908B2 (en) | 2018-11-29 | 2021-05-25 | Pfizer Inc. | Chemical compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR76950B (enExample) * | 1980-12-18 | 1984-09-04 | Wellcome Found | |
| FR2680512B1 (fr) * | 1991-08-20 | 1995-01-20 | Adir | Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| AU668818B2 (en) * | 1993-04-07 | 1996-05-16 | Taiho Pharmaceutical Co., Ltd. | Thiazolidine derivative and pharmaceutical composition containing the same |
| EP0923580A1 (en) * | 1996-07-26 | 1999-06-23 | Dr. Reddy's Research Foundation | Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof |
| US6184228B1 (en) * | 1999-05-25 | 2001-02-06 | Anadys Pharmaceuticals, Inc. | Anti-sickling agents: selection methods and effective compounds |
| AUPQ105499A0 (en) * | 1999-06-18 | 1999-07-08 | Biota Scientific Management Pty Ltd | Antiviral agents |
| US20030022923A1 (en) * | 2001-03-01 | 2003-01-30 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
| EP1567490B1 (en) | 2002-12-04 | 2011-10-05 | Virginia Commonwealth University | Anti-sickling agents |
| NZ548049A (en) * | 2003-12-02 | 2009-01-31 | Celgene Corp | Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
| DE102008027574A1 (de) * | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
| TW201139406A (en) * | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
| US20120122928A1 (en) * | 2010-08-11 | 2012-05-17 | Bayer Cropscience Ag | Heteroarylpiperidine and -Piperazine Derivatives as Fungicides |
| DK3738434T3 (da) * | 2011-12-28 | 2023-12-04 | Global Blood Therapeutics Inc | Mellemprodukter til opnåelse af substituerede benzaldehydforbindelser og fremgangsmåder til anvendelse deraf ved øgning af vævsoxygenering |
| BR112015021982B1 (pt) * | 2013-03-15 | 2022-12-13 | Global Blood Therapeutics, Inc | Compostos e seus usos para a modulação de hemoglobina |
-
2014
- 2014-03-10 AU AU2014237361A patent/AU2014237361A1/en not_active Abandoned
- 2014-03-10 AP AP2015008720A patent/AP2015008720A0/xx unknown
- 2014-03-10 EA EA201591427A patent/EA201591427A1/ru unknown
- 2014-03-10 EP EP14768414.6A patent/EP2970315B1/en active Active
- 2014-03-10 ES ES14768414T patent/ES2909634T3/es active Active
- 2014-03-10 KR KR1020157024775A patent/KR20150132147A/ko not_active Withdrawn
- 2014-03-10 SG SG11201507351PA patent/SG11201507351PA/en unknown
- 2014-03-10 MX MX2015011509A patent/MX388013B/es unknown
- 2014-03-10 WO PCT/US2014/022846 patent/WO2014150289A1/en not_active Ceased
- 2014-03-10 PE PE2015001920A patent/PE20151907A1/es not_active Application Discontinuation
- 2014-03-10 JP JP2016501086A patent/JP6401772B2/ja active Active
- 2014-03-10 CA CA2902721A patent/CA2902721C/en active Active
- 2014-03-10 CN CN201480013378.3A patent/CN105209469A/zh active Pending
- 2014-03-10 BR BR112015021980A patent/BR112015021980A2/pt not_active IP Right Cessation
- 2014-03-13 UY UY35425A patent/UY35425A/es not_active Application Discontinuation
- 2014-03-13 TW TW103108889A patent/TW201518286A/zh unknown
-
2015
- 2015-08-26 IL IL240845A patent/IL240845A0/en unknown
- 2015-09-01 ZA ZA2015/06390A patent/ZA201506390B/en unknown
-
2018
- 2018-09-07 JP JP2018167981A patent/JP2018188481A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016512824A (ja) | 2016-05-09 |
| MX388013B (es) | 2025-03-19 |
| EA201591427A1 (ru) | 2016-01-29 |
| KR20150132147A (ko) | 2015-11-25 |
| SG11201507351PA (en) | 2015-10-29 |
| JP2018188481A (ja) | 2018-11-29 |
| EP2970315A4 (en) | 2016-08-17 |
| EP2970315A1 (en) | 2016-01-20 |
| MX2015011509A (es) | 2016-05-31 |
| AP2015008720A0 (en) | 2015-09-30 |
| BR112015021980A2 (pt) | 2017-07-18 |
| ZA201506390B (en) | 2017-03-29 |
| WO2014150289A1 (en) | 2014-09-25 |
| TW201518286A (zh) | 2015-05-16 |
| EP2970315B1 (en) | 2021-09-15 |
| JP6401772B2 (ja) | 2018-10-10 |
| IL240845A0 (en) | 2015-10-29 |
| AU2014237361A1 (en) | 2015-09-17 |
| ES2909634T3 (es) | 2022-05-09 |
| CA2902721A1 (en) | 2014-09-25 |
| PE20151907A1 (es) | 2016-01-20 |
| CA2902721C (en) | 2021-09-14 |
| CN105209469A (zh) | 2015-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35427A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
| UY35426A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
| MX2015011448A (es) | Compuestos y sus usos para modular la hemoglobina. | |
| MX388013B (es) | Compuestos y usos de estos para la modulación de la hemoglobina. | |
| MX2015003140A (es) | Formulaciones de enzalutamida. | |
| MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
| CO7101245A2 (es) | Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido | |
| MX2013012896A (es) | Compuestos novedosos como moduladores de proteina cinasas. | |
| CR20150316A (es) | Compuestos y sus métodos de empleo | |
| CO2018005315A2 (es) | Moduladores de la interacción de sestrina-gator2 y sus usos | |
| ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
| EA201992707A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
| GT201400164A (es) | Compuestos de imidazopirrolidinona | |
| MX374399B (es) | Composiciones y sus usos para tratar y prevenir la enfermedad de huntington. | |
| MX2013012053A (es) | Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos. | |
| MX2016004340A (es) | Compuestos heterociclicos y usos de los mismos. | |
| MX351028B (es) | Determinadadas entidades, composiciones y metodos quimicos. | |
| CL2013002517A1 (es) | Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer. | |
| GT201400222A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
| UY34725A (es) | Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos. | |
| CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| UY34773A (es) | Ácidos indanoiloxidihidrobenzofuranilacéticos como moduladores de la actividad de gpr40, composiciones que los contienen y sus usos | |
| MX2019012428A (es) | Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo. | |
| CR20150585A (es) | Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20211112 |